Collegium Pharmaceutical (COLL)

• Market cap: $1.12B
• 1 day: -0.22%
• 5 days: -5.68%
• 1 month: -6.94%
• 3 months: 20.72%
• 6 months: 19.78%
• Year to date: 24.14%
• 1 year: -4.92%
• 5 years: 80.41%
• 10 years: 49.64%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Employees: 357

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2,088% more call options, than puts

Call options by funds: $372K | Put options by funds: $17K

6% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 83

4% less capital invested

Capital invested by funds: $1.1B [Q1] → $1.05B (-$43.5M) [Q2]

5.86% less ownership

Funds ownership: 116.78% [Q1] → 110.92% (-5.86%) [Q2]

8% less funds holding

Funds holding: 241 [Q1] → 221 (-20) [Q2]

41% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 34

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $44
• Avg. target: $44
• High target: $44

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Brandon Folkes

$44

Buy Assumed

11 Aug 2025